CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

Phase 1 Unknown 15 enrolled Kai Lin Xu; Jun Nian Zheng Nanjing Bioheng Biotech Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety and feasibility of CTA101 in treating patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.

Timeline

Start: 2019-12-10
Primary completion: 2021-11
Completion: 2022-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CTA101	Cell therapy	—	Intravenous

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

Summary

Timeline

Drugs

Indications